[CAS NO. 680188-33-4] Ibalizumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [680188-33-4]

Catalog

HY-P99028

Brand

MCE

CAS

680188-33-4

DESCRIPTION [680188-33-4]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Ibalizumab]

For research use only. We do not sell to patients.

Summary

Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor . Ibalizumab has the potential for HIV-1 infection research ^[1] .

IC50 & Target

HIV-1

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02475629	TaiMed Biologics Inc.	HIV	August 2015	Phase 3
NCT02028819	University of Colorado, Denver	Human Immunodeficiency Virus (HIV)	January 2012
NCT00089700	Tanox	HIV Infections	March 2004	Phase 2
NCT00784147	TaiMed Biologics Inc.	HIV	August 2008	Phase 2
NCT05495204	Epividian\|Theratechnologies\|FIECON	HIV-1-infection	August 5, 2022
NCT01292174	TaiMed Biologics Inc.\|Aaron Diamond AIDS Research Center\|Bill and Melinda Gates Foundation	Prevention of Infection With HIV-1	February 2011	Phase 1
NCT05388474	Theratechnologies\|Research Organization (KC) Ltd.\|Excelsus Statistics Inc.\|Health Psychology Research Group (HPR)\|ICON Clinical Research	HIV Infections\|Multi-Antiviral Resistance	March 22, 2022
NCT01056393	Kaiser Permanente\|TaiMed Biologics Inc.	HIV Infections	November 2009	Phase 2
NCT02707861	TaiMed Biologics Inc.\|Westat	HIV	March 2016	Phase 3

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785.